Online citations, reference lists, and bibliographies.

Assessment Of Plasma Total Tau Level As A Predictive Biomarker For Dementia And Related Endophenotypes

Matthew P Pase, Alexa Beiser, Jayandra J Himali, Claudia L. Satizabal, Hugo J. Aparicio, Charles DeCarli, Geneviève Chêne, Carole Dufouil, Sudha Seshadri
Published 2019 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
Importance Blood-based biomarkers have the potential to improve the identification of persons with the greatest dementia risk for inclusion in dementia prevention trials through low-cost and minimally invasive screening. Objective To investigate the use of plasma total tau as a blood biomarker for dementia and related endophenotypes. Design, Setting, and Participants This prospective cohort study used data from the US community-based Framingham Heart Study with replication in the Memento study, a multicenter cohort of persons with mild cognitive impairment or subjective cognitive complaints recruited from memory clinics across France. Total tau levels were measured from stored plasma samples in Framingham Heart Study participants during 2004 to 2011. Dementia follow-up occurred across a median of 6 years (interquartile range, 5-8 years) for persons 65 years and older who were dementia free at baseline. Plasma and/or cerebrospinal fluid samples were obtained from Memento study participants from April 19, 2011, to June 22, 2016. Dementia follow-up took place over a median of 4 years (interquartile range, 3-5 years). Data analysis was performed from January to November 2018. Exposures Plasma total tau level measured using single-molecule array technology. Main Outcomes and Measures Incidence of dementia of any cause (all dementia) and dementia due to clinical Alzheimer disease (AD dementia). Results Among the 1453 participants in the Framingham dementia study sample, the mean (SD) age was 75 (7) years; 792 (54.5%) were female. Among the 367 individuals in the replication cohort, the mean (SD) age was 69 (9) years; 217 (59.1%) were female. Of 134 cases of incident all dementia in the Framingham sample, 105 were AD dementia. After adjustment for age and sex, each SD unit increase in the log of plasma total tau level was associated with a 35% increase in AD dementia risk (hazard ratio [HR], 1.35; 95% CI, 1.10-1.67). The addition of plasma total tau to a model including age and sex improved the stratification of participants for risk of AD dementia (net reclassification improvement, 0.382; 95% CI, 0.030-0.716). Higher plasma total tau level was associated with poorer cognition across 7 cognitive tasks (P < .05) and smaller hippocampi (hippocampal volume: &bgr; [SE] = 0.002 [0.001]; P = .003) as well as neurofibrillary tangles (&bgr; [SE] = 0.95 [0.45]; P = .04) and microinfarcts (odds ratio, 3.04; 95% CI, 1.26-7.37) at autopsy. In the replication cohort, plasma total tau level weakly correlated with cerebrospinal fluid total tau level (Spearman correlation coefficient, 0.16; P = .07), but plasma total tau was at least as strongly associated with incident AD dementia as cerebrospinal fluid total tau (log plasma total tau: HR, 2.33; 95% CI, 1.00-5.48; log cerebrospinal fluid total tau: HR, 2.14; 95% CI, 1.33-3.44) after adjustment for age and sex. Conclusions and Relevance The findings suggest that plasma total tau levels may improve the prediction of future dementia, are associated with dementia endophenotypes, and may be used as a biomarker for risk stratification in dementia prevention trials.
This paper references
10.1212/WNL.52.6.1158
The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer’s disease
André Delacourte (1999)
10.1212/WNL.42.1.115
Prevalence of dementia and probable senile dementia of the Alzheimer type in the Framingham Study
David L. Bachman (1992)
10.1126/scitranslmed.3007941
The A4 Study: Stopping AD Before Symptoms Begin?
Reisa A. Sperling (2014)
10.2105/AJPH.41.3.279
Epidemiological approaches to heart disease: the Framingham Study.
Thomas R. Dawber (1951)
10.1093/aje/kwm021
The Third Generation Cohort of the National Heart, Lung, and Blood Institute's Framingham Heart Study: design, recruitment, and initial examination.
Greta Lee Splansky (2007)
10.1021/ac103161b
Simultaneous detection of single molecules and singulated ensembles of molecules enables immunoassays with broad dynamic range.
David Michael Rissin (2011)
10.1371/journal.pmed.1002254
APOE-related risk of mild cognitive impairment and dementia for prevention trials: An analysis of four cohorts
Jing Qian (2017)
10.1186/s13195-017-0288-0
Cognitive and imaging markers in non-demented subjects attending a memory clinic: study design and baseline findings of the MEMENTO cohort
Carole Dufouil (2017)
10.1038/ng.2802
Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease
Jean-Charles Lambert (2013)
10.1056/NEJMoa1504327
Incidence of Dementia over Three Decades in the Framingham Heart Study.
Claudia L. Satizabal (2016)
10.1161/STROKEAHA.117.013369
Role of Improved Vascular Health in the Declining Incidence of Dementia
Matthew P Pase (2017)
10.1016/j.neurobiolaging.2004.05.004
Measures of brain morphology and infarction in the framingham heart study: establishing what is normal
Charles DeCarli (2005)
10.3233/JAD-161114
Plasma Tau Association with Brain Atrophy in Mild Cognitive Impairment and Alzheimer's Disease.
Kacie D. Deters (2017)
10.1016/j.jalz.2016.06.001
Levels of tau protein in plasma are associated with neurodegeneration and cognitive function in a population-based elderly cohort
Jeffrey L. Dage (2016)
10.1016/S0887-6177(03)00039-8
Trail Making Test A and B: normative data stratified by age and education.
Tom N. Tombaugh (2004)
10.1097/WAD.0b013e31827bde32
Defining MCI in the Framingham Heart Study Offspring: education versus WRAT-based norms.
Richard E. Ahl (2013)
10.1161/01.STR.0000150668.58689.f2
Anatomical mapping of white matter hyperintensities (WMH): exploring the relationships between periventricular WMH, deep WMH, and total WMH burden.
Charles DeCarli (2005)
10.1016/j.jalz.2011.03.003
Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Reisa A. Sperling (2011)
10.1212/WNL.0000000000003246
Plasma tau in Alzheimer disease
Niklas Mattsson (2016)
10.1016/j.neuroimage.2009.02.018
Multi-atlas based segmentation of brain images: Atlas selection and its effect on accuracy
Paul Aljabar (2009)
10.5860/choice.29-2400
A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary
Otfried Spreen (1991)
10.2174/156720512801322609
The Framingham Brain Donation Program: neuropathology along the cognitive continuum.
Rhoda Au (2012)
10.1109/EMBC.2012.6347195
Adaptive image segmentation for robust measurement of longitudinal brain tissue change
Evan Fletcher (2012)
10.1001/jamaneurol.2017.1359
Association of Plasma Total Tau Level With Cognitive Decline and Risk of Mild Cognitive Impairment or Dementia in the Mayo Clinic Study on Aging
Michelle M. Mielke (2017)
10.1186/alzrt163
Plasma tau levels in Alzheimer's disease
Henrik Zetterberg (2013)
10.1016/j.resuscitation.2012.07.027
Tau proteins in serum predict neurological outcome after hypoxic brain injury from cardiac arrest: results of a pilot study.
Jeffrey D. Randall (2013)
10.1002/sim.4085
Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers.
Michael J Pencina (2011)
10.1093/acrefore/9780199975839.013.104
Diagnostic and Statistical Manual of Mental Disorders
Janet B. W. Williams (2013)
10.1038/s41598-017-08779-0
Tau plasma levels in subjective cognitive decline: Results from the DELCODE study
Stephan Müller (2017)
10.1109/EMBC.2012.6345882
MRI non-uniformity correction through interleaved bias estimation and B-spline deformation with a template
Evan Fletcher (2012)
10.2217/17520363.2.4.363
Tau as a biomarker of neurodegenerative diseases.
Susanna Schraen-Maschke (2008)
10.1016/j.jalz.2018.02.018
NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease
Clifford R. Jack (2018)
10.1016/0022-3956(75)90026-6
"Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.
Marshal F. Folstein (1975)
10.1212/WNL.34.7.939
Clinical diagnosis of Alzheimer's disease
Guy Mckhann (1984)
10.1016/0091-7435(75)90037-7
The Framingham Offspring Study. Design and preliminary data.
Manning Feinleib (1975)
10.1002/sim.4780141909
Confidence interval estimates of an index of quality performance based on logistic regression models.
David W. Hosmer (1995)
10.1007/BF00308809
Neuropathological stageing of Alzheimer-related changes
Heiko Braak (1991)
10.1002/sim.2929
Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond.
Michael J Pencina (2008)
10.1016/S1474-4422(16)00070-3
CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis
Bob Olsson (2016)
10.1038/nbt.1641
Single-Molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations
David Michael Rissin (2010)



This paper is referenced by
10.3390/diagnostics10050326
Role of Body-Fluid Biomarkers in Alzheimer’s Disease Diagnosis
Thuy Loan Chi Nguyen (2020)
10.1016/j.neurobiolaging.2020.05.011
A longitudinal examination of plasma neurofilament light and total tau for the clinical detection and monitoring of Alzheimer's disease
Michael A. Sugarman (2020)
10.1016/j.smrv.2019.101250
Obstructive sleep apnea, cognition and Alzheimer's disease: A systematic review integrating three decades of multidisciplinary research.
Omonigho M Bubu (2019)
10.1007/s15005-019-0209-9
Tau-Proteinwerte im Blut als valider Marker der frühen Alzheimer-Erkrankung
Thomas Duning (2019)
10.1002/ana.25542
Plasma total-tau as a biomarker of stroke risk in the community.
Matthew P Pase (2019)
10.1055/a-0985-8210
Bluttests für die Alzheimer-Erkrankung: Aktueller Stand und ethische Implikationen
Frank Jessen (2019)
10.1212/wnl.0000000000008866
Effects of acute sleep loss on diurnal plasma dynamics of CNS health biomarkers in young men
Christian Benedict (2020)
10.3389/fneur.2019.00715
Plasma Amyloid Beta and Tau Levels Are Predictors of Post-stroke Cognitive Impairment: A Longitudinal Study
Nai-Fang Chi (2019)
10.3233/JAD-200046
Plasma Amyloid Concentration in Alzheimer’s Disease: Performance of a High-Throughput Amyloid Assay in Distinguishing Alzheimer’s Disease Cases from Controls
Insa Feinkohl (2020)
10.1016/j.neurobiolaging.2019.10.010
Profile of pathogenic proteins in total circulating extracellular vesicles in mild cognitive impairment and during the progression of Alzheimer's disease
Morgane Perrotte (2020)
Identification d'un profil de marqueurs périphériques lié aux scores cognitifs dans le plasma et les vésicules extracellulaires durant le développement de la maladie d'Alzheimer: évolution de marqueurs liés au stress oxydatif et aux mécanismes physiopathologiques.
Morgane Perrotte (2019)
10.1186/s13041-019-0448-1
Blood-based molecular biomarkers for Alzheimer’s disease
Henrik Zetterberg (2019)
10.1177/1756286419888819
Latest advances in cerebrospinal fluid and blood biomarkers of Alzheimer’s disease
Marta Milà-Alomà (2019)
10.1002/mco2.1
Plasma pTau181 as a biomarker for Alzheimer's disease
Jie Meng (2020)
10.1038/s41591-020-0755-1
Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia
Shorena Janelidze (2020)
10.1371/journal.pone.0225178
Detection of early-stage Alzheimer’s pathology using blood-based autoantibody biomarkers in elderly hip fracture repair patients
Cassandra Demarshall (2019)
10.1038/s41582-020-0348-0
An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders
Nicholas James Ashton (2020)
10.14283/jpad.2019.20
Blood Tests for Alzheimer’s Disease and Related Disorders
Eric M. Reiman (2019)
10.1007/s00401-019-02087-9
From the prion-like propagation hypothesis to therapeutic strategies of anti-tau immunotherapy
Morvane Colin (2019)
10.1016/j.neuro.2019.09.017
Occupational metals exposure and cognitive performance among foundry workers using tau protein as a biomarker.
Rateba S Mohammed (2019)
10.1212/WNL.0000000000008682
Association of CD14 with incident dementia and markers of brain aging and injury
Matthew P Pase (2020)
10.1016/j.conb.2019.11.019
An update on fluid biomarkers for neurodegenerative diseases: recent success and challenges ahead
Joel Simrén (2020)
10.1093/brain/awaa054
Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study
Frank de Wolf (2020)
10.1007/s40120-019-00164-5
An Update on Blood-Based Markers of Alzheimer’s Disease Using the SiMoA Platform
Danni Li (2019)
10.1007/s40120-019-00167-2
Advance in Plasma AD Core Biomarker Development: Current Findings from Immunomagnetic Reduction-Based SQUID Technology
Lih-Fen Lue (2019)
Semantic Scholar Logo Some data provided by SemanticScholar